Out of stock
ব্যবসার জন্য পাইকারি দামে পণ্য কিনতে রেজিস্টেশন করুন
Register
0 People recently viewed this
Daunobin
Healthcare Pharmaceuticals Ltd.
Generic: Daunorubicin
Safety Advices
বাংলা
English
CONSULT YOUR DOCTOR
It is not known whether it is safe to consume alcohol with Daunobin. Please consult your doctor.
CONSULT YOUR DOCTOR
Daunobin is unsafe to use during pregnancy as there is definite evidence of risk to the developing baby. However, the doctor may rarely prescribe it in some life-threatening situations if the benefits are more than the potential risks. Please consult your doctor.
UNSAFE
Daunobin is unsafe to use during breastfeeding. Data suggests that the drug may cause toxicity to the baby.
UNSAFE
Daunobin may cause side effects which could affect your ability to drive.
CAUTION
Daunobin should be used with caution in patients with kidney disease. Dose adjustment of Daunobin may be needed. Please consult your doctor.
Use of Daunobin is not recommended in patients with severe kidney disease.
CAUTION
Daunobin should be used with caution in patients with liver disease. Dose adjustment of Daunobin may be needed. Please consult your doctor.
Use of Daunobin is not recommended in patients with severe liver disease.
Medicine Overview of Daunobin 20mg/4ml Injection
Introduction
Daunobin is used for the treatment of blood cancer (leukemia). It works by interfering with the growth of cancer cells, which are eventually destroyed. Daunobin is given under the supervision of a healthcare professional and should not be self-administered. It might be given as a single therapy or in combination with some other medication. Your doctor will decide what dose is necessary and how often you need to take it. This will depend on what you are being treated for and may change from time to time. You should take it exactly as your doctor has advised. Taking it in...
... Show moreUses of Daunobin
- Blood cancer
Side effects of Daunobin
Common
- Nausea
- Vomiting
- Low blood platelets
- Ulcer
- Abdominal pain
- Loss of appetite
- Decreased white blood cell count
- Hair loss
- Fever
- Decreased blood cells (red cells, white cells, and platelets)
- Fatigue
- Anemia (low number of red blood cells)
- Chills
- Diarrhea
- Mucosal inflammation
- Febrile neutropenia
- Stomatitis (Inflammation of the mouth)
- Breathing problems
How to use Daunobin
Your doctor or nurse will give you this medicine. Kindly do not self administer.
How Daunobin works
Daunobin is an anti-cancer medication. It works by damaging the genetic material (DNA) of the cancer cells and stops their growth and multiplication.
Quick Tips
- You must undergo careful examination of functioning of the heart as daunorubicin is known to cause life-threatening heart problems due to damage to heart muscles (myocardium).
- Daunorubicin should be used cautiously is elderly, children, and patients with high blood pressure (manifest arterial hypertension) due to increased risk of developing heart complications.
- You may be frequently examined for complete blood-count (blood cells, proteins, hemoglobin), kidney, liver and heart function before and during the course of treatment.
- Tell your doctor if you have had, have an ongoing or scheduled radiation therapy or X-ray of the chest area. Daunorubicin increases the risk of reactions at the site of radiation therapy (or risk of heart problem if the chest area is involved) and should be used cautiously.
- You should be monitored for worsening of infections and development of life-threatening infections (e.g. viral infections like herpes zoster) as daunorubicin is known to suppress the activity of the immune system.
- Liposomal preparation of daunorubicin is not recommended for use in children <18 years.
- Before starting daunorubicin treatment, make sure that you are free from any side effects of previous chemotherapy (inflammation of the mouth, abnormal blood cell counts and generalized infections).
- Both partners should take extreme care to avoid pregnancy while on daunorubicin therapy and consult your doctor if you get to know that you are pregnant.
Brief Description
Indication
Acute leukaemia, AIDS-related Kaposi's sarcoma
Administration
IV Preparation
Reconstitute 20 mg vial with 4 mL SWI to a final concentration of 5 mg/mL
IV Administration
Vesicant, never administer IM or SC
IVP: desired dose is withdrawn into a syringe containing 10-15 mL NS, then injected over 2-3 min into the tubing or sidearm of a freely flowing IV infusion of NS or D5W
Has also been diluted in 100 mL of D5W or NS & infused over 30-45 min
Flush with 5-10 mL of IV solution before & after drug administration
Adult Dose
Acute Nonlymphocytic Leukemia
In combination with cytarabine 100 mg/m²/day IV for 7 days first course, for 5 days subsequent courses
60 years old: 30 mg/m² IVP days 1, 2, 3 first course; days 1, 2 subsequent courses
Acute Lymphocytic Leukemia
45 mg/m² IVP days 1, 2, 3
Hepatic Impairment
3 mg/dL serum bilirubin: 50% of regular dose
Child Dose
Acute Nonlymphocytic Leukemia
2 years old or >0.5 m² BSA: 25 mg/m² IVP qWeek
Acute Lymphocytic Leukemia
2 years old or >0.5 m² BSA: 25 mg/m² IVP qWeek
Renal Dose
Renal Impairment
>3 mg/dL serum creatinine: Administer 50% regular dose
Contraindication
Heart failure. Pregnancy, lactation.
Mode of Action
Daunorubicin forms a stable complex with DNA and interferes with the nucleic acid synthesis. It is a cell-cycle nonspecific agent, but its cytotoxic effects are mostly marked in the S-phase. It also has immunosuppressant and antibacterial effects.
Precaution
Regular blood count and ECG monitoring; elderly, children. Hepatic or renal impairment may increase risk of toxicity. Pre-existing cardiac disease and previous treatment with doxorubicin. Myocardial toxicity leading to potentially fatal congestive heart failure may occur during therapy or mth to yr after therapy cessation. Incidence of myocardial toxicity increases after total cumulative dose exceeds 400-550 mg/m2 in adults, 300 mg/m2 in children >2 yr, or 10 mg/kg in children <2 yr. Risk of severe myelosuppression leading to infection or haemorrhage.
Lactation: excretion in milk unknown/not recommended
Side Effect
>10%
Nausea,Vomiting,Arrhythmias,Discoloration of urine,Alopecia
1-10%
Injection site skin flare,Hyperuricemia,GI ulceration,Diarrhea
<1%
Arrythmia,Cardiomyopathy,Bilirubin increased,Pruritus,Urticaria
Frequency Not Defined
Fever,CHF,Flushing,Stomatitis,Myelosuppression,Rash,Hyperpigmentation of previously radiated areas,Transverse pigmentation of fingernails and toenails,Fertility impairment
Potentially Fatal: Bone marrow suppression, cardiac toxicity, cardiomyopathy and congestive heart failure.
Pregnancy Category Note
Pregnancy Category: D
Lactation: excretion in milk unknown/not recommended
Interaction
Increased risk of cardiotoxicity when used with cyclophosphamide. Increased risk of hepatic toxicity when used with hepatotoxic drugs e.g. high-dose methotrexate.
Potentially Fatal: Immunisation with live vaccines is not recommended. Concurrent radiation may lead to increased radiation reaction.
ব্যবসার জন্য পাইকারি দামে পণ্য কিনতে রেজিস্টেশন করুন
Register
